Author

Eva Szegezdi

Lecturer in Biochemistry, National University of Ireland, Galway - Cited by 19,837 - Tumour microenvironment - Cancer stem cell - Apoptosis - Leukemia - Cancer biology

Biography

Eva Szegezdi is a Research Lecturer in Cancer Biology and principal investigator at the Apoptosis Research Centre, National University of Ireland, Galway. Dr. Szegezdi received her Ph. D. in medical science in 2000 studying cell death signalling at the University of Debrecen, Hungary.
Title
Cited by
Year
Guidelines for the use and interpretation of assays for monitoring autophagy
DJ Klionsky, K Abdelmohsen, A Abe, MJ Abedin, H Abeliovich, ...Autophagy 12 (1), 1-222, 201612139201
12139
2016
Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling
T Sessler, S Healy, A Samali, E SzegezdiPharmacology & therapeutics 140 (2), 186-199, 2013201
127
2013
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
ES Marianne van Dijk, Anna Halpin-McCormick, TamasCell Death and Disease 4, 2013201
82
2013
N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
F Dufour, T Rattier, S Shirley, G Picarda, AA Constantinescu, A Morlé, ...Cell Death & Differentiation 24 (3), 500-510, 2017201
80
2017
TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
F Dufour, T Rattier, AA Constantinescu, L Zischler, A Morlé, HB Mabrouk, ...Oncotarget 8 (6), 9974, 2017201
69
2017
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
M Gurney, A Stikvoort, E Nolan, L Kirkham-McCarthy, S Khoruzhenko, ...Haematologica 107 (2), 437, 2022202
55
2022
Involvement of planned cell death of necroptosis in cancer treatment by nanomaterials: Recent advances and future perspectives
M Sharifi, SH Hosseinali, AA Saboury, E Szegezdi, M FalahatiJournal of controlled release 299, 121-137, 2019201
49
2019
The Janus face of death receptor signaling during tumor immunoediting
E O’Reilly, A Tirincsi, SE Logue, E SzegezdiFrontiers in immunology 7, 446, 2016201
47
2016
NOXA contributes to the sensitivity of PERK-deficient cells to ER stress
S Gupta, Z Giricz, A Natoni, N Donnelly, S Deegan, E Szegezdi, A SamaliFEBS letters 586 (22), 4023-4030, 2012201
35
2012
Recreating complex pathophysiologies in vitro with extracellular matrix surrogates for anticancer therapeutics screening
ZDI Shologu N, Szegezdi E, Lowery A, Kerin M, Pandit ADrug Discovery Today, 2016201
32
2016
Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML
E O’Reilly, SPS Dhami, DV Baev, C Ortutay, A Halpin-McCormick, ...Scientific Reports 8 (1), 15752, 2018201
32
2018
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: Apoptosis induction by TRAIL
E Szegezdi, D Mahalingamregulation 37, 353-373, 2012201
31
2012
Targeting TRAIL towards the clinic
D Mahalingam, C NAM Oldenhuis, E Szegezdi, F J Giles, E GE de Vries, ...Current drug targets 12 (14), 2079-2090, 2011201
30
2011
The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
DV Baev, J Krawczyk, E SzegezdiLeukemia research reports 3 (2), 79-82, 2014201
30
2014
The pyrrolo-1, 5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic …
SM Nathwani, LM Greene, S Butini, G Campiani, DC Williams, A Samali, ...International Journal of Oncology 49 (1), 74-88, 2016201
25
2016
Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing
SPS Dhami, SS Kappala, A Thompson, E SzegezdiDrug discovery today 21 (9), 1464-1471, 2016201
22
2016
BCL-2 modulates the unfolded protein response by enhancing splicing of X-box binding protein-1
TN Chonghaile, S Gupta, M John, E Szegezdi, SE Logue, A SamaliBiochemical and biophysical research communications 466 (1), 40-45, 2015201
16
2015
Recreating the bone marrow microenvironment to model leukemic stem cell quiescence
E O’Reilly, HA Zeinabad, C Nolan, J Sefy, T Williams, M Tarunina, ...Frontiers in cell and developmental biology, 2319, 2021202
6
2021
Theranostic drug test incorporating the bone‐marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy
SPS Dhami, A Tirincsi, D Baev, J Krawczyk, J Quinn, MR Cahill, ...British Journal of Haematology 189 (6), e24-e28, 2020202
5
2020
Guiding the killer and bringing in accomplices: Bispecific antibody treatment for malignant melanoma
E Szegezdi, M LeverkusJournal of Investigative Dermatology 136 (2), 362-364, 2016201
5
2016

Referred From: https://scholar.google.com/citations?user=6uQy0vAAAAAJ&hl=en

Cited by
Citations 19837
h-index 37
i10-index 58
Recommended Journals
Open Access Journals